Teresa I. Navas

FDA investigator · also recorded as Oe Thi Eresa Navas, Sens Teresa I. Navas

Appears on 21 documents from 2020 to 2024, mostly at sites in India. Most often cites production record review (21 CFR 211.192).

21
Documents on file
5.3
Observations per 483
2020
First seen
2024
Most recent

What they cite most

From 108 observations

Activity by year

2020: 1, 2021: 1, 2022: 5, 2023: 8, 2024: 6

Where

India 13 · Japan 6 · Canada 1 · Florida 1

Is Teresa I. Navas coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

21 documents, newest first
FirmOpen
483 Alembic Pharmaceuticals LimitedNov 22, 2024 · Jarod, India
483 Global Calcium Pvt. LimitedAug 2, 2024 · Hosur, India
483 Biocon Biologics LimitedJul 26, 2024 · Bengalurn, India
483 AURORE PHARMACEUTICALS PRIVATE LIMITEDMay 31, 2024 · Hyderabad, India
483 Eugia Steriles Private LimitedApr 5, 2024 · Anakapalli, India
483 Mitsubishi Tanabe Pharma Factory Ltd.Jan 19, 2024 · Onoda, Japan
483 Central Glass CO., LTD.Sep 15, 2023 · UBE, Japan

About this profile

What does Teresa I. Navas inspect?

Teresa I. Navas appears on 21 documents on file covering 21 sites, mostly in India.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.160 and 21 CFR 211.68.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Teresa I. Navas is dated Nov 22, 2024.